Alirocumab
Praluent (alirocumab) is an antibody pharmaceutical. Alirocumab was first approved as Praluent on 2015-07-24. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
Trade Name | Praluent |
---|---|
Common Name | Alirocumab |
Indication | atherosclerosis, dyslipidemias, hypercholesterolemia |
Drug Class | Monoclonal antibodies: fully human, cardiovascular indications |
